Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of experimental mouth rinse formulations compared to a positive control mouth rinse and a hydroalcohol control mouth rinse for the reduction of gingivitis and plaque when used as an adjunct to tooth brushing during a six-week product usage period.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Healthy Reference Group Participants who are identified as healthy will be a comparison group. This group will participate in the examinations and plaque sampling only and will not receive a prophylaxis or product. |
Other: Colgate® Cavity Protection Toothpaste
Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Other: Concept Curve Winter Series Toothbrush
Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
|
| Experimental: 5% Hydroalcohol Mouthrinse (Negative control) Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 milliliter (mL) of 5 percent (%) Hydroalcohol Mouthrinse twice daily (morning and evening) up to 6 weeks. |
Other: Colgate® Cavity Protection Toothpaste
Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Other: Concept Curve Winter Series Toothbrush
Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Other: 5% Hydroalcohol Mouthrinse
Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
|
| Experimental: Listerine® Cool Mint® (Positive control) Participants after brushing with Colgate® Cavity protection toothpaste and Concept curve winter series Toothbrush will rinse mouth for 30 seconds with 20 mL of Listerine® Cool Mint® twice daily (morning and evening) up to 6 weeks. |
Other: Colgate® Cavity Protection Toothpaste
Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Other: Listerine® Cool Mint®
Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
Other: Concept Curve Winter Series Toothbrush
Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
|
| Experimental: Mouthrinse Prototype 1 Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 1 twice daily (morning and evening) up to 6 weeks. |
Other: Colgate® Cavity Protection Toothpaste
Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Other: Concept Curve Winter Series Toothbrush
Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Other: Mouthrinse Prototype 1
Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
|
| Experimental: Mouthrinse Prototype 2 Participants after brushing with Colgate® Cavity protection toothpaste and Concept Curve winter series toothbrush will rinse mouth for 30 seconds with 20 mL of Mouthrinse Prototype 2 twice daily (morning and evening) up to 6 weeks. |
Other: Colgate® Cavity Protection Toothpaste
Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
Other: Concept Curve Winter Series Toothbrush
Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
Other: Mouthrinse Prototype 2
Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
|
Outcome Measures
Primary Outcome Measures
- Whole-mouth Mean Modified Gingival Index (Mean MGI) After 6 Weeks of Product Use [6 weeks]
Gingivitis will be assessed by the Modified Gingival Index on the buccal and lingual marginal gingivae and interdental papillae of all scorable teeth: 0 (Normal [absence of inflammation]), 1 (Mild inflammation [slight change in color, little change in texture] of any portion of the entire gingival unit); 2 (Mild inflammation of the entire gingival unit); 3 (Moderate inflammation [moderate glazing, redness, edema, and/or hypertrophy] of the gingival unit); 4 (Severe inflammation [marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration] of the gingival unit).
- Whole-mouth Mean Plaque Index (Mean PI) After 6 Weeks of Product Use [6 weeks]
Plaque area will be scored by the Turesky modification of the Quigley-Hein Plaque Index, on 6 surfaces (distobuccal, midbuccal and mesiobuccal, distolingual, midlingual and mesiolingual) of all scorable teeth, following disclosing: 0 (No Plaque); 1 (Separate flecks or discontinuous band of plaque around the gingival (cervical) margin); 2 (Thin (up to 1 millimeter [mm]), continuous band of plaque at the gingival margin); 3 (Band of plaque wider than 1mm but less than1/3 of the surface); 4 (Plaque covering 1/3 or more, but less than 2/3 of the surface); 5 (Plaque covering 2/3 or more of the surface).
Secondary Outcome Measures
- Whole-mouth Mean Plaque Index (Mean PI) After 4 Weeks of Product Use [4 weeks]
Plaque area will be scored by the Turesky modification of the Quigley-Hein Plaque Index, on 6 surfaces (distobuccal, midbuccal and mesiobuccal, distolingual, midlingual and mesiolingual) of all scorable teeth, following disclosing: 0 (No Plaque); 1 (Separate flecks or discontinuous band of plaque around the gingival (cervical) margin); 2 (Thin (up to 1 millimeter [mm]), continuous band of plaque at the gingival margin); 3 (Band of plaque wider than 1mm but less than1/3 of the surface); 4 (Plaque covering 1/3 or more, but less than 2/3 of the surface); 5 (Plaque covering 2/3 or more of the surface).
- Whole-mouth Mean Modified Gingival Index (Mean MGI) After 4 Weeks of Product Use [4 weeks]
Gingivitis will be assessed by the Modified Gingival Index on the buccal and lingual marginal gingivae and interdental papillae of all scorable teeth: 0 (Normal [absence of inflammation]), 1 (Mild inflammation [slight change in color, little change in texture] of any portion of the entire gingival unit); 2 (Mild inflammation of the entire gingival unit); 3 (Moderate inflammation [moderate glazing, redness, edema, and/or hypertrophy] of the gingival unit); 4 (Severe inflammation [marked redness and edema/hypertrophy, spontaneous bleeding, or ulceration] of the gingival unit).
- Whole-mouth Mean Expanded Bleeding Index (Mean BI) After 4 and 6 Weeks of Product Use [4 and 6 Weeks]
Bleeding will be assessed according to the Expanded Gingival Bleeding Index, 168 Sites. A periodontal probe with a 0.5 millimeter (mm) diameter tip will be inserted into the gingival crevice and swept from distal to mesial around the tooth at an angle of approximately 60 degree, while in contact with the sulcular epithelium. Each of 6 gingival areas (distobuccal, mid-buccal, mesiobuccal, distolingual, mid-lingual, and mesiolingual) around each tooth will be assessed. After approximately 30 seconds, bleeding at each gingival unit will be recorded according to the following scale: 0 (Absence of bleeding after 30 seconds); 1 (Bleeding after 30 seconds); 2 (Immediate bleeding).
- Percentage of Bleeding Sites, Based on the Expanded Gingival Bleeding Index After 4 and 6 Weeks of Product Use [4 and 6 Weeks]
Percent bleeding sites will be calculated by taking the total number of sites with bleeding score greater than 0 divided by the total number of sites assessed for each participant. Bleeding will be assessed according to the Expanded Gingival Bleeding Index, 168 Sites. A periodontal probe with a 0.5 millimeter (mm) diameter tip will be inserted into the gingival crevice and swept from distal to mesial around the tooth at an angle of approximately 60 degree, while in contact with the sulcular epithelium. Each of 6 gingival areas (distobuccal, mid-buccal, mesiobuccal, distolingual, mid-lingual, and mesiolingual) around each tooth will be assessed. After approximately 30 seconds, bleeding at each gingival unit will be recorded according to the following scale: 0 (Absence of bleeding after 30 seconds); 1 (Bleeding after 30 seconds); 2 (Immediate bleeding).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adequate oral hygiene (That is brush teeth daily and exhibit no signs or oral neglect)
-
A minimum of 20 gradable teeth including 4 molars with scorable facial and lingual surfaces. Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, teeth with veneers, or third molars will not be included in the tooth count
-
A mean gingival index greater than or equal to (>=) 1.95 per the Modified Gingival Index at Baseline (for those in the randomized treatment group)
-
A mean gingival index less than or equals to (<=) 0.75 per the Modified Gingival Index at Baseline (for those in the healthy reference group)
-
A mean plaque index >= 1.95 per the 6 site Turesky modification of the Quigley-Hein Plaque Index at Baseline (for those in randomized treatment groups)
-
Greater than or equal to 10 percent (%) bleeding sites at baseline (for those in randomized treatment groups)
Exclusion Criteria:
-
History of significant adverse effects, including sensitivities or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses and red food dye
-
Dental prophylaxis within four weeks prior to Screening/Baseline 1 visit
-
More than three sites that have periodontal pockets depths measuring 5mm or greater in depth
-
Teeth having periodontal pocket depths measuring more than 3 mm in depth (healthy reference group)
-
History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures
-
Use of Antibiotics, anti-inflammatory or anticoagulant therapy, phenytoin sodium or diphenylhydantoin, calcium channel blockers, cyclosporin A, immunostimulants/ immunomodulators during the study or within the one month prior to the Baseline 1 exam. Intermittent use of certain anti-inflammatory medication is acceptable at the discretion of the Investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Salus Research, Inc. | Fort Wayne | Indiana | United States | 46825 |
Sponsors and Collaborators
- Johnson & Johnson Consumer Inc. (J&JCI)
Investigators
- Principal Investigator: Jeffery Milleman, DDS, Salus Research, Inc.
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CCSORC001793
- CCSORC001793